August 15th 2023
Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.
Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.
August 8th 2023
Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.
August 1st 2023
Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.
Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.
July 25th 2023
A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.
Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.
November 22nd 2022
Rana R. McKay, MD, discusses the pros and cons of utilizing triplet therapy in the frontline treatment of patients with renal cell carcinoma.
November 4th 2022
Rana R. McKay, MD, discusses four key trials that have advanced the frontline treatment of metastatic renal cell carcinoma in the modern era.
October 11th 2021
Rana R. McKay, MD, discusses the outcomes of landmark clinical trials in frontline renal cell carcinoma.
October 23rd 2020